Cryoport FY 2025 earnings snapshot

Cryoport (CYRX) has reported its FY 2025 fourth quarter with revenue of US$45.5 million and a basic EPS loss of US$0.21, alongside net income from continuing operations showing a loss of US$10.5 million. The company has seen quarterly revenue track between US$41.0 million and US$45.5 million across FY 2025, while basic EPS losses ranged from US$0.17 to US$0.23 per share, providing a clear picture of consistent top line scale but ongoing bottom line pressure. For investors, the mix of steady revenue and persistent losses keeps the focus firmly on how margins evolve from here.

See our full analysis for Cryoport.

With the headline numbers reported, the next step is to see how this earnings profile lines up with the widely held market stories about Cryoport, and where the data pushes back on those narratives.

Losses Narrowing Over Five Years

• Over the trailing 12 months, Cryoport recorded a net loss from continuing operations of US$42.0 million and basic EPS of US$0.84 in losses, compared with a five year trend where losses have been reduced at about 12.3% per year.
• Supporters of the bullish view argue that this multi year improvement in losses, combined with Cryoport backing roughly 70% of cell and gene clinical trials, sets the company up for stronger earnings power over time. However, the latest quarterly net losses between US$8.7 million and US$11.7 million through FY 2025 show that the path to profitability is still very much a work in progress.
  • The bullish narrative highlights potential margin gains from services like IntegriCell and facility investments. At the same time, the reported trailing loss of US$42.0 million underlines how much margin expansion would be needed to reach those outcomes.
  • Backers of the optimistic case often focus on future scenarios where margins align with a 14.2% industry level. However, the current basic EPS loss of US$0.84 over the last year keeps that view highly dependent on further execution.

Bulls argue that this gradual improvement is the foundation for a strong rebound in future margins, but the latest loss figures show how much work is still ahead before that story plays out. 🐂 Cryoport Bull Case

DCF Value Far Below US$8.74 Price

• Cryoport trades at a share price of US$8.74 while the supplied DCF fair value is US$1.70, and at the same time the trailing P/S multiple of 2.5x sits below both peer average of 3.2x and US Life Sciences industry average of 2.9x.
• Critics in the bearish camp point to this gap as a key issue, arguing that even with revenue growth of 7.9% a year and reduced losses, the stock still prices in more optimism than the current cash flow estimate and ongoing unprofitability support.
  • Bears highlight that forecasts indicate Cryoport is not expected to reach profitability in the next three years. This contrasts with a market price more than 5x the DCF fair value of US$1.70 in the analysis.
  • At the same time, the lower 2.5x P/S multiple versus peers can appeal to value minded investors, so the bearish view leans heavily on the continued net loss of US$42.0 million over the last year to argue that the discount on sales alone may not be enough.

Skeptics warn that this tension between a discounted P/S and a low DCF fair value is exactly where investors need to slow down and weigh the risk of paying too much for future growth. 🐻 Cryoport Bear Case

Modest 7.9% Revenue Growth

• Trailing revenue growth of 7.9% a year, based on US$176.2 million over the last 12 months, sits below a 10.2% US market benchmark, while quarterly revenue across FY 2025 has ranged between US$41.0 million and US$45.5 million.
• The consensus style narrative sees this steady expansion in revenue as a support for long term demand in cell and gene logistics, but pairs it with caution around customer concentration and ongoing investment in new services that have yet to fully offset the current run rate of losses.
  • Supporters of the balanced view point to recurring BioStorage and bioservices growth and a broadened customer base as positives, yet the trailing loss of US$42.0 million shows that these revenue streams are not yet covering the cost base.
  • That same narrative flags higher regulatory and infrastructure costs as possible headwinds. This would matter a lot when revenue growth is 7.9% a year rather than matching or exceeding the 10.2% broader US market benchmark.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Cryoport on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With mixed views across bulls, bears, and the middle ground, it is worth checking the numbers for yourself and forming a clear stance. To see what stands out on both sides of the argument, take a look at the 1 key reward and 2 important warning signs.

See What Else Is Out There

Cryoport is still carrying a US$42.0 million loss over the last year, with basic EPS in the red and profitability yet to be reached.

If that level of ongoing losses feels uncomfortable, you might want to scan our 77 resilient stocks with low risk scores to focus on companies with more resilient financial profiles right now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.